Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on April 21, 2020, with the earliest event reported on the same date. The filing discloses the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
The Company entered into a securities purchase agreement to sell the following instruments:
- Common Stock: 1,910,000 shares.
- Pre-funded Warrants: Warrants to purchase up to 2,090,000 shares of common stock.
- Common Stock Warrants: Warrants to purchase up to 4,000,000 shares of common stock.
Pricing Structure:
- Common stock and accompanying warrants were sold at a combined price of $5.00 per share/warrant.
- Pre-funded warrants and accompanying warrants were sold at a combined price of $4.999 per warrant/warrant.
- Common stock warrants have an exercise price of $5.00 and expire five years from issuance.
- Pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
Transaction Costs:
- Co-Placement Agents received a cash fee equal to 7% of gross cash proceeds.
- The Company reimbursed Roth Capital Partners, LLC for out-of-pocket expenses not to exceed $75,000.
Note: The filing text does not provide the total gross proceeds, net proceeds, or specific cash flow, revenue, or debt figures.
Material Changes and Restrictions
The securities purchase agreement includes a 90-day lock-up provision prohibiting the Company from issuing additional common stock or equivalents, with exceptions for equity compensation plans, outstanding rights, or certain strategic transactions. The offering was priced on April 21, 2020, and closed on April 24, 2020.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard indemnification provisions for the Co-Placement Agents. The transaction is subject to the terms of the registration statement and securities purchase agreement referenced in the exhibits.
Key Facts for Investor Verification
- Verify the total gross proceeds raised from the sale of 1,910,000 shares and 2,090,000 pre-funded warrants.
- Confirm the dilution impact of the 4,000,000 accompanying warrants and the pre-funded warrants on existing shareholders.
- Review the full Securities Purchase Agreement (Exhibit 1.2) for specific redemption rights or anti-dilution provisions not detailed in the summary.
- Check the press release filed as Exhibit 99.2 for the final closing details and use of proceeds.